EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

miR-221 and miR-222 in Pancreatic Ductal Adenocarcinoma: Mechanistic Evidence, Extracellular Vesicle Communication, Biomarker Candidates, and Therapeutic Prospects

Ghaleb Oriquat, Waleed K Abdulsahib, S Renuka Jyothi, Priya Priyadarshini Nayak, Ashish Singh Chauhan, Siya Singla, Fadhil Faez Sead, Djamila Polatova

Cancer Treatment and Research Communications · 2026-10 · 101515

DOI: 10.1016/j.ctarc.2026.101515 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Treatment and Research Communications, 2026-10. Verfasst von Ghaleb Oriquat und 7 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Allied Medical Sciences, Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan. Electronic address: g…. Die Arbeit nennt 199 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic ductal adenocarcinoma (PDAC) remains difficult to diagnose early and treat effectively. The related microRNAs miR-221 and miR-222 share a seed sequence, but their functions and clinical evidence should be evaluated individually. Pancreatic cancer models support miR-221/222-associated TIMP-2 repression and invasion, miR-222-mediated p57 regulation, and tumor-derived vesicular miR-222 effects on p27 expression and localization. Macrophage-derived extracellular vesicular miR-222-3p has also been implicated in gemcitabine resistance through TSC1-associated signaling. By contrast, the TRPS1-ZEB2 mechanism and the vesicular SPINT1-HGF liver pathway derive from breast and colorectal cancer studies, respectively, and remain extrapolations when discussed in PDAC. Circulating miR-221 has shown exploratory diagnostic associations, but results from general miRNA panels cannot be assigned to miR-221 or miR-222 individually. Tissue prognostic associations likewise do not validate circulating assays. A first-in-human study of the selective inhibitor LNA-i-miR-221 provides early safety and peripheral-blood pharmacodynamic evidence in a mixed advanced-cancer population that included pancreatic cancer; it does not establish PDAC-specific efficacy. Translation requires independent biomarker validation, molecule-specific target-dependence studies, and confirmation of effective pancreatic tumor delivery.

Schlagwörter

Stichwörter der Autor:innen

ChemoresistanceCirculating biomarkersEpithelial–mesenchymal transitionExosomesLNA antisense oligonucleotideLiquid biopsyOncomiRPancreatic ductal adenocarcinomamiR-221miR-222

Autor:innen und Institutionen

  • Faculty of Allied Medical Sciences, Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan. Electronic address: goreqat@ammanu.edu.jo.
  • Department of Pharmacology and Toxicology, College of Pharmacy, Al Farahidi University, Baghdad, Iraq. Electronic address: waleedk.abdulsahib@uoalfarahidi.edu.iq.
  • Department of Biotechnology and Genetics, School of Sciences, JAIN (Deemed to be University), Bangalore, Karnataka, India. Electronic address: j.renuka@jainuniversity.ac.in.
  • Department of Medical Oncology, IMS and SUM Hospital, Siksha 'O' Anusandhan (Deemed to be University), Bhubaneswar, Odisha, 751003, India. Electronic address: drpriya.sjh@gmail.com.
  • Uttaranchal Institute of Pharmaceutical Sciences, Division of research and innovation, Uttaranchal University, Dehradun, Uttarakhand, India. Electronic address: ashishchauhan.pharmacy@gmail.com.
  • Centre for Research Impact & Outcome, Chitkara University Institute of Engineering and Technology, Chitkara University, Rajpura, 140401, Punjab, India. Electronic address: siyasingla0202@outlook.com.

Zitieren

APA

Oriquat, G., Abdulsahib, W. K., Jyothi, S. R., Nayak, P. P., Chauhan, A. S., Singla, S., Sead, F. F., & Polatova, D. (2026). miR-221 and miR-222 in Pancreatic Ductal Adenocarcinoma: Mechanistic Evidence, Extracellular Vesicle Communication, Biomarker Candidates, and Therapeutic Prospects. Cancer Treatment and Research Communications, 101515. https://doi.org/10.1016/j.ctarc.2026.101515

Vancouver

Oriquat G, Abdulsahib WK, Jyothi SR, Nayak PP, Chauhan AS, Singla S, et al. miR-221 and miR-222 in Pancreatic Ductal Adenocarcinoma: Mechanistic Evidence, Extracellular Vesicle Communication, Biomarker Candidates, and Therapeutic Prospects. Cancer Treatment and Research Communications. 2026:101515. doi:10.1016/j.ctarc.2026.101515

BibTeX
@article{Oriquat2026,
  author = {Oriquat, Ghaleb and Abdulsahib, Waleed K and Jyothi, S Renuka and Nayak, Priya Priyadarshini and Chauhan, Ashish Singh and Singla, Siya and Sead, Fadhil Faez and Polatova, Djamila},
  title = {miR-221 and miR-222 in Pancreatic Ductal Adenocarcinoma: Mechanistic Evidence, Extracellular Vesicle Communication, Biomarker Candidates, and Therapeutic Prospects},
  journal = {Cancer Treatment and Research Communications},
  year = {2026},
  pages = {101515},
  doi = {10.1016/j.ctarc.2026.101515}
}
Kostenlos starten →